CANOC

HIV rates still rising in Canada, but treatment is simpler, safer and effective

For those newly infected and diagnosed with HIV in Canada, if they seek treatment right away, the long-term outlook is quite different than it used to be. “The news is very good compared to 20 years ago…a young person diagnosed with HIV today, a young adult, who begins therapy shortly thereafter and takes therapy every […]

HIV rates still rising in Canada, but treatment is simpler, safer and effective Read More »

Switching from first-line ART with suppressed viral load linked to treatment failure

People who switch away from their initial antiretroviral therapy (ART) regimen when their viral load is undetectable may have a higher likelihood of subsequent virological failure, researchers reported at the 20th International AIDS Conference last week in Melbourne. However, the association varied across groups and the researchers suggested their findings may reflect issues such as

Switching from first-line ART with suppressed viral load linked to treatment failure Read More »

DISENTANGLING IDU AND HCV IMPACTS ON HIV OUTCOMES IN CANADIANS

Canadians coinfected with HIV and hepatitis C virus (HCV) had a worse response to antiretroviral therapy (ART) and a higher death rate if they had an injection drug use (IDU) history. The findings could clarify understanding of how HCV affects HIV infection. CANOC Collaboration investigators observed that worse clinical outcomes seen in HIV/HCV-coinfected people may

DISENTANGLING IDU AND HCV IMPACTS ON HIV OUTCOMES IN CANADIANS Read More »

Research Profile – Going Non-Viral: Achieving HIV Suppression

A collaboration of researchers is studying a comprehensive dataset of over 8,000 people on antiretroviral HIV therapies to assess how Canada is dealing with the HIV/AIDS epidemic. A Canadian living with the human immunodeficiency virus (HIV) is most likely to achieve “viral suppression” if they are male, reside in Ontario and have no history of

Research Profile – Going Non-Viral: Achieving HIV Suppression Read More »

Study finds regional variation in treatment outcomes and HIV risk factors among HIV-positive Canadian women

Results will help develop effective prevention and HIV management programs Vancouver, British Columbia (May 19, 2010) – Researchers from British Columbia, Ontario and Quebec revealed findings from a new national study today that showed HIV risk factors and clinical indicators for Canadian women vary significantly among provinces. Researchers affiliated with the Canadian Observational Cohort (CANOC),

Study finds regional variation in treatment outcomes and HIV risk factors among HIV-positive Canadian women Read More »

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below